On April 14, Cue Biopharma announced that it will receive a $7.5 million milestone payment from Boehringer Ingelheim for the development of the CUE-501 compound. This payment follows the approval of the first compound for lead optimization under their collaboration agreement. The company could earn up to an additional $337.5 million in future milestone and royalty payments.
Labcorp (NYSE: LH) has officially launched the first U.S.-manufactured, FDA-cleared rapid fentanyl urine visual test, marking a significant milestone in clinical diagnostics. Designed specifically for emergency departments and hospitals, the test delivers critical results within just 10 minutes. By detecting…
Read the full storyBoehringer Ingelheim and Zai Lab have expanded their clinical collaboration to evaluate a novel combination therapy targeting the DLL3 protein. Zai Lab recently announced new clinical data demonstrating that zocilurtatug pelitecan (formerly ZL-1310) induces rapid and robust intracranial responses in SCLC patients with…
Cosmos Health Inc. (COSM) reported record 2025 revenue of $65.27 million, driven by an 83% surge in gross profit and significant operational expansion across its Sky Premium Life and Cana Laboratories divisions. In a strategic update, the company announced the integration of AI across its operations, which is…
Beeline Medicines has officially launched as a new biotech entity, secured by a substantial $300 million funding commitment from Bain Capital. The startup has successfully licensed five experimental immunology assets from pharmaceutical giant Bristol Myers Squibb (BMY). The company's lead candidate, afimetoran, is…